| abstract |
The present disclosure relates to a method of treating cancer comprising administering a therapeutically effective amount of an EZH2 inhibitor to a subject in need thereof, the cancer comprising at least one derived from stem cells, progenitor cells, or immature cells. Characterized by one cancer cell, the at least one cancer cell comprises one or more genetic damage that confers on the cancer cell a dependency on EZH2 function. In certain embodiments, an EZH2 inhibitor of the present disclosure is tazemethostat or a pharmaceutically acceptable salt thereof. |